Thus, PD treatment represents one of the most promising cancer therapies of the moment [241, 250–252], with checkpoint inhibitors comprising both, PD-1 and PD-L1 targeting therapeutic antibodies in clinical trials (see Tables 1–4 in [252]). Here, CD274 is linked to cancer.